For women with ovarian cancer, early identification of BRCA mutations can help determine the most appropriate treatment plan, and if the mutation is germline, can also support
Whilst germline BRCA testing for women with ovarian cancer is now commissioned by NHS England, funding for tumour BRCA testing remains limited.4,5 Therefore, to support identification of these women, AstraZeneca is providing a tumour BRCA testing service at certain sites in the UK for patients who meet the eligibility criteria.
Here you can find out more about BRCA testing, what the AstraZeneca
About tumour BRCA testing
Tumour BRCA testing offers the ability to detect if a patient has a BRCA1/2 mutation which may be somatic or germline due to more sensitive laboratory techniques.7,8 Therefore, it allows a subset of ovarian cancer patients the chance to be diagnosed as having a BRCA mutation who may have otherwise gone undiagnosed.